NEVADA CANCER INSTITUTE Patent applications |
Patent application number | Title | Published |
20120294869 | Methods for Treating Fatty Liver Disease - The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of uridine or a compound that modulates one or more uridine phosphorylases in a subject in need thereof. | 11-22-2012 |
20080318241 | Methods and Systems for Detecting Antiangiogenesis - The present invention provides methods and systems for the detection of tumor vessel response to antiangiogenic therapies. The present invention also provides compositions and methods for therapeutic and research applications. In particular, the present invention provides systems and methods that employ CD26, HIF-1, and HIF-1 pathway components as biomarkers for monitoring antiangiogenic therapies and as therapeutic targets. | 12-25-2008 |
20080299077 | ISOLATION AND GROWTH OF STEM CELLS FROM HEMANGIOMAS - The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions. | 12-04-2008 |
20080241110 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) - The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS, AML and other forms of leukemia. | 10-02-2008 |